NCI CIP-Net
@nci-cipnet.org
Official BlueSky account of the NCI Cancer Immunoprevention Network (CIP-Net). www.nci-cipnet.org
Pinned
NCI CIP-Net
@nci-cipnet.org
· Dec 12
CIP-Net
nci-cipnet.org
The Cancer Immunoprevention Network (CIP-Net), established by the National Cancer Institute (NCI), advances the understanding of fundamental immunoprevention mechanisms, drives the discovery of novel strategies, and supports the preclinical development and testing of new interventions
nci-cipnet.org
nci-cipnet.org
#CIPNetPublication in Nature Cancer by Dr. Madhav Dhodapkar:
The MyCheckpoint randomized trial reports durable clinical responses in multiple myeloma following TIGIT or LAG3 immune checkpoint blockade, with distinct pathway-specific immune correlates for each arm.
pubmed.ncbi.nlm.nih.gov/39187595/
The MyCheckpoint randomized trial reports durable clinical responses in multiple myeloma following TIGIT or LAG3 immune checkpoint blockade, with distinct pathway-specific immune correlates for each arm.
pubmed.ncbi.nlm.nih.gov/39187595/
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial - PubMed
Persons with myeloma were randomized to receive an anti-TIGIT (T cell immunoreceptor) or anti-LAG3 (lymphocyte activation gene) antibody followed by combination with pomalidomide and dexamethasone ( NCT04150965 ). Primary and secondary endpoints were safety and efficacy, respectively. Therapy was we …
pubmed.ncbi.nlm.nih.gov
December 22, 2025 at 8:37 PM
#CIPNetPublication in Nature Cancer by Dr. Madhav Dhodapkar:
The MyCheckpoint randomized trial reports durable clinical responses in multiple myeloma following TIGIT or LAG3 immune checkpoint blockade, with distinct pathway-specific immune correlates for each arm.
pubmed.ncbi.nlm.nih.gov/39187595/
The MyCheckpoint randomized trial reports durable clinical responses in multiple myeloma following TIGIT or LAG3 immune checkpoint blockade, with distinct pathway-specific immune correlates for each arm.
pubmed.ncbi.nlm.nih.gov/39187595/
The Cancer Immunoprevention Network (CIP-Net), established by the National Cancer Institute (NCI), advances the understanding of fundamental immunoprevention mechanisms, drives the discovery of novel strategies, and supports the preclinical development and testing of new interventions
nci-cipnet.org
nci-cipnet.org
CIP-Net
nci-cipnet.org
December 12, 2025 at 6:14 PM
The Cancer Immunoprevention Network (CIP-Net), established by the National Cancer Institute (NCI), advances the understanding of fundamental immunoprevention mechanisms, drives the discovery of novel strategies, and supports the preclinical development and testing of new interventions
nci-cipnet.org
nci-cipnet.org